Products

What will AGI do for Boceprevir?

This classification denotes a protease inhibitor and antiviral with the molecular formula C27H45N5O5, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 89BT58KELH, chemically known as (1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-[(2S)-2-(tert-butylcarbamoylamino)-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide but generally known as Boceprevir, which bears US NIH Compound Identifier 10324367. Boceprevir most often comes in base and sulfate forms. European Medicines Agency schedules Boceprevir in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31579. The term BOCEPREVIR is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, No. 1, 2008, List 59.). As of Q4 2014, BOCEPREVIR remains the US FDA Preferred Term for this commodity. SMILES: CC1(C2C1C(N(C2)C(=O)C(C(C)(C)C)NC(=O)NC(C)(C)C)C(=O)NC(CC3CCC3)C(=O)C(=O)N)C.

How AGI delivers it

Four ways AGI delivers for Boceprevir

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Boceprevir, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Boceprevir, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Boceprevir connects

measured by

  • Active Ingredient Potencymodel
  • Chiral Enantiomeric Excessmodel
  • Compound Puritymodel
  • Particle Sizemodel
  • Residual Solventmodel